The EXTEND Study
A Clincal Trial for People Newly Diagnosed with Type 1 Diabetes
EXTEND is a clinical trial testing whether a therapy called tocilizumab (Actemra®) can stop the immune system from attacking the remaining beta cells in those recently diagnosed with type 1 diabetes and possibly extend the ability to naturally produce insulin. If you have been diagnosed with type 1 diabetes within the last 3 months, you maybe eligible to particpate.
EXTEND is being conducted by the Immune Tolerance Network and TrialNet and is sponsored by the National Institute of Allergy and Infectious Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases (NIH funded). For more information, visit www.extendstudy.org
- Inspiration 100%
- Illustrator 50%
- After Effects 40%
- Premier 10%